Drugs / N-3C01
last change Jun 2026 re-read 2 minutes ago

N-3C01

Developed for
cancer
Investigated by
Hefei Xinzhu Biological Technology Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07639450 Jun 2026 → Aug 2028 expected cancer Hefei Xinzhu Biological Technology Co., Ltd. Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as N-3C01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07639450
Route Subcutaneous “administered subcutaneously” NCT07639450